In Brief: Elan/RTP Pharma
Elan/RTP Pharma: Companies establish The Cyclosporine Company, an Ireland-based partnership chaired by RTP Pharma CEO Gary Pace, PhD. Elan will invest $12.5 mil. in equity and debt in RTP, part of which may be converted into up to 50% of TCC. Both companies will contribute their work on cyclosporine reformulations to TCC, including RTP's Insoluble Drug Delivery oral and injectable formulations and a combination oral dose formulation with omega 3 fatty acids...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth